Latest From Tesaro Inc.
The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.
US Pharmaceuticals President Jack Bailey will step down, to be succeeded by Maya Martinez-Davis, currently at Merck KGAA.
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.
The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.
- Specialty Pharmaceuticals
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Tesaro Inc.
- Senior Management
Lonnie Moulder, CEO
Timothy Pearson, EVP, CFO
Mary Lynne Hedley, PhD, Pres. & COO
Grant C Bogle, SVP, Chief Commercial Officer
William Aitchison, PhD, SVP, Technical ops
Allene Diaz, SVP, Global Commercial Development
Joseph Farmer, SVP, General Counsel & Corp Secretary
Martin Huber, MD, SVP, CMO
Jennifer Jackson, PhD, SVP, Global RA and QA
Orlando Oliveira, SVP, International
- Contact Info
Phone: (339) 970-0900
1000 Winter St.
Waltham, MA 02451
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.